The Medical Letter on Drugs and Therapeutics
Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved blinatumomab (Blincyto – Onyx/Amgen) for treatment of relapsed or refractory Philadelphia chromosome-negative (Ph-) B-cell precursor acute lymphoblastic leukemia (ALL).

TREATMENT OF ALL – Induction therapy usually includes vincristine, a glucocorticoid, and an anthracycline, with or without asparaginase. Patients with Ph+ ALL may also receive a targeted agent such as imatinib (Gleevec). For non-responders or patients who respond initially and then relapse, allogeneic hematopoietic stem cell transplantation is potentially curative.

MECHANISM OF ACTION – Blinatumomab is a bispecific CD19-directed CD3 T-cell engager. It binds to CD19, a protein found on the surface of most B-precursor lymphoblasts, and CD3, a protein on T-cell lymphocytes. It activates endogenous T-cells by connecting CD3 in the T-cell receptor complex with CD19 on benign and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia (online only)
Article code: 1468e
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian